Verve Therapeutics
Manufacturing · Massachusetts, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
201 Brookline Ave, Boston, Massachusetts...Phone Number
(617) 603-0070Website
www.vervetx.comRevenue
$59.6 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
3
1
1
1
1
1
About Verve Therapeutics
Verve Therapeutics is a clinical-stage cardiovascular gene editing company focused on the development of single-course gene editing medicines designed to permanently reduce the risk of cardiovascular disease by editing genes in the liver that regulate cholesterol and triglyceride metabolism.Explore more
Verve Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Verve Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Verve Therapeutics recently announced quarterly report
Check if Verve Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Check out if Verve Therapeutics is spiking on competitors!
Click to see if Verve Therapeutics had a recent Job posting/layoffs
Verve Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Verve Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Verve Therapeutics
Product Launch: Get notified when Verve Therapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Verve Therapeutics
Compare insights from companies similar to Verve Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
<$5M
51-200
Private
$147.5M
2018
RR
Renuka RamanathanVice President Head of Corporate & Business Development
Company Profile Activity
Activity Insights
Verve Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Verve Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Verve Therapeutics.
Verve Therapeutics financials insights
Gather financial insights about Verve Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$63M
2021
Series B
$94M
Stock Offering
$306.7M
Verve Therapeutics Tech Stack
A closer look at the technologies used by Verve Therapeutics
See more technologies
Most Recent Scoops
Person-Based
Medical Research
Person-Based
Medical Research, Pharmaceuticals
Left Company
Executive Move
Executive Moves, Left Company
Person-Based
Medical Research, Pharmaceuticals
Person-Based
Medical Research, Pharmaceuticals
Verve Therapeutics News & Media
Eli Lilly (NYSE:LLY) Eyes US$1.3 Billion Acquisition Of Verve Therapeutics - Yahoo Finance
Eli Lilly (NYSE:LLY) recently saw its stock price rise by 6.63% over the last month, a movement potentially influenced by significant events such as its advanced negotiations to acquire gene editing startup Verve Therapeutics for up to $1.3 billion. This acquisition aligns with Lilly's focus on expanding its pipeline of experimental medicines. Additionally, the company engaged in a global partnership with Juvena Therapeutics, which could further enhance its portfolio. Despite broader market...Eli Lilly lands “bargain” deal to acquire Verve Therapeutics for $1.3bn
Eli Lilly’s buyout of the genetic medicine developer adds to lofty big pharma spending in 2025.Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
Verve's leading programs aim to deliver lifelong cardiovascular risk reduction with a single dose by targeting genes strongly linked to cardiovascular disease Lilly's established capabilities in cardiometabolic disease and genetic medicines are highly complementary to Verve's vision and...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Verve Therapeutics
Sign Up For FreeTo access detailed company insights
Verve Therapeutics is a clinical-stage cardiovascular gene editing company focused on the development of single-course gene editing medicines designed to permanently reduce the risk of cardiovascular disease by editing genes in the liver that regulate cholesterol and triglyceride metabolism.... Read More
